Teva looks to revolutionize Type 1 diabetes therapy with Sanofi cast-off; Drugmaker in talks to buy old Pfizer facility;

@FiercePharma: FDA gets interim club to fight drug shortages. News | Follow @FiercePharma

> Teva Pharmaceutical Industries ($TEVA) is seeking to transform DiaPep277, a compound once rejected by Sanofi ($SNY) into the first treatment to succeed insulin for Type 1 diabetes. News

> An as yet unnamed drugmaker is taking over much of the former Pfizer ($PFE) complex near Terre Haute, IN that had housed roughly 800 workers before it was shut down. Story

> Members of an Australian class action lawsuit who blame a Grunenthal's anti-morning sickness drug, Thalidomide, for causing birth defects have won the right to have their case heard in their own country. Article

> A Mylan ($MYL) subsidiary has received approval for three antiretroviral therapies used to treat HIV/AIDS under the WHO's prequalification of medicines program. Mylan release

> China Sky One Medical Chairman and CEO Yanqing Liu is taking a sick leave. Jianping Li, the company's GM and a board director, will oversee the day-to-day operations of the company until Liu can return. News

Biotech News

@FierceBiotech: Analysts: AstraZeneca may need to change R&D strategy after setbacks with olaparib, TC-5214. News | Follow @FierceBiotech

@JohnCFierce: Says a lot about Somaxon that its shouts of "help" are being largely ignored this a.m. as it struggles to stay afloat. | Follow@JohnCFierce

@RyanMFierce: Lilly is paying $20M upfront to ImmunoGen to use $IMGN's antibody-drug-conjugate tech in cancer. Release | Follow @RyanMFierce

 @MaureenFierce: Diana Zuckerman talks to @Pharmalot about the Plan B decision. Short version: "It's a no-win situation." Article | Follow @MaureenFierce

@MarkHFierce: There's a way now to keep a cancer patient's healthy cells and tumor cells alive in the lab. Two ingredients help. Release | Follow @MarkHFierce

> Bayer predicts blockbuster success for four of its late-stage drugs. News

> AstraZeneca buries one program as second drug stumbles again in PhIII. Article

> Blockbuster hopes for Rasilez fade at Novartis. More

Biotech Research News

> Scientists keep patient's tumor, healthy cells alive in lab. Item

> Discovery could lead to memory pill for Alzheimer's patients. Story

> Sirt1, in excess, could protect against Huntington's disease. Report

> NIH suspends grants for new biomedical chimp research. News

Manufacturing News

> FDA gets interim club to fight drug shortages. Item

> Eli Lilly bulks up in Ireland. Report

> Celltrion boasts worldwide tech lead in biosimilars. Article

> Sanofi's Shan5 vaccine to restart in 2013. Report

> Catalent rethinks stainless for new bio plant. News

And Finally... The hormone DHEA, which is mostly secreted by the adrenal glands, may be able to help women who are going through menopause and could also give them better sex lives, according to a study. Item

Suggested Articles

Gilead Sciences has found a new chief financial officer in an appointment that has mergers and acquisitions written all over it.

Pfizer's role as the hero in ramping up production of a chemo drug badly needed by pediatric oncologists is a turnabout for the drugmaker.

Johnson & Johnson is dealing with $2 billion in patent losses in 2019, but has 10 drugs growing at double-digit percentages, executives said Tuesday.